Regional distribution to recovery of 5-HT levels after administration of "atrophins" MDMA and D,L-fenfluramine. Stereospecificity and comparison with 5,7-dihydroxytryptamine.
Lehmann
J
J
Department of Mental Health Services, Hahnemann University, Philadelphia, Pennsylvania 19102-1192.
DeSouza
E B
EB
Culp
S
S
Zaczek
R
R
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D015104:3,4-Methylenedioxyamphetamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000633:toxicity; D015116:5,7-Dihydroxytryptamine / Q000008:administration & dosage / Q000633:toxicity*; D000818:Animals; D001284:Atrophy; D001921:Brain / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D002552:Cerebral Ventricles / Q000187:drug effects / Q000473:pathology / Q000502:physiology*; D015198:Designer Drugs / Q000633:toxicity; D004298:Dopamine / Q000378:metabolism; D005277:Fenfluramine / Q000008:administration & dosage / Q000633:toxicity*; D006719:Homovanillic Acid / Q000378:metabolism; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D007276:Injections, Intraventricular; D008297:Male; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D009638:Norepinephrine / Q000378:metabolism; D009928:Organ Specificity; D017374:Paroxetine; D010880:Piperidines / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D012701:Serotonin / Q000378:metabolism*; D013237:Stereoisomerism
D015198:Designer Drugs; D010880:Piperidines; D015102:3,4-Dihydroxyphenylacetic Acid; D005277:Fenfluramine; D015116:5,7-Dihydroxytryptamine; D012701:Serotonin; D017374:Paroxetine; D015104:3,4-Methylenedioxyamphetamine; D006897:Hydroxyindoleacetic Acid; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D004298:Dopamine; D009638:Norepinephrine; D006719:Homovanillic Acid